Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this project is to evaluate a novel inhibitor of the 12/15 lipoxygenase (12/15-LOX)…

Active Cooperative Agreement Awarded Last action

Award ID
U01NS132332
Recipient
Awarding agency
Obligated
$2,951,289

Award facts

Completion date 99% complete
Originally
Place of performance
Palo Alto, CA 94303, USA

Award details come from USAspending.gov.

Description

Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this project is to evaluate a novel inhibitor of the 12/15 lipoxygenase (12/15-LOX) enzyme in preclinical rodent models of ischemic stroke within the span network. To this end, BPN-27332 will be tested in comparison with other preclinical stroke treatments under rigorous conditions in multiple laboratories. 12/15-LOX has been shown to be up-regulated in the ischemic peri-infarct area in both rodents and humans. IT contributes to both neuronal cell death, as well as to weakening of the blood - brain barrier and edema formation. ALOX15(-/-) mice in which the gene encoding 12/15-LOX has been knocked out, are protected in models of transient focal ischemia. Through the NIH blueprint neurotherapeutics program we have developed BPN-27332, a novel and highly selective inhibitor of 12/15-LOX. In a mouse model of transient focal ischemia, BPN-27332 reduces infarct size when given in the acute phase. Protection is long lasting, with significant behavioral benefits still seen four weeks after the experimental stroke with excellent adme and PK/PD properties. We now propose to test BPN-27332 in a blinded fashion in comparison with vehicle, but also with other treatment modalities. In aim 1, the compound is subjected to rigorous quality control measures, including verification of identity and purity by hplc and mass spectrometry and in vitro efficacy testing. In aim 2, the compound will be shipped to the coordinating center for distribution to the testing sites, where BPN-27332 will be extensively tested in rodent models of ischemic stroke. Successful completion of these studies will ready BPN-27332 for clinical trials in human patients, which will hopefully lead to a much needed new treatment option for patients with ischemic strokes.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $225,729
Amendment -$192,784
Amendment -$192,784
Amendment $225,729
Amendment $225,729
Amendment -$192,784
Amendment $309,667
Amendment $309,667
Amendment $309,667
Amendment $309,667
Amendment $0
Amendment $0
Amendment $312,234
Amendment $312,234
Amendment $312,234
Amendment $338,542
Original award $338,542
Show all 20

Subawards

Subrecipient Amount Awarded
University Of California Santa Cruz The Holman laboratory will formulate the lipoxygenase inhibitors and determine their stability relative to time and solvent. $34,452
University Of Southern California The Coordinating Center (CC) provides scientific and organizational leadership to SPAN to achieve both efficiency and excellence in the implementation and… $365,868

Quick answers

Who received award U01NS132332?

U01NS132332 was awarded to Loxagen Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on May 1, 2023.

How much is award U01NS132332 worth?

$2,951,289 has been obligated on U01NS132332.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award